ELISA Against PT. Sera were stored at -80'C to be used in the ELISA. The ELISA method was a modified version of that described by Engvall and Perlman (9) . Flat-bottomed polystyrene microtest plates (Dynatech Laboratories, Inc., Alexandria, VA) were preincubated for 30 min at 37'C in a humidified chamber to minimize the electrostatic activity of the solid phase. The wells of each plate were then coated with 100 gl of purified goat anti-PT Igs (prepared at Sclavo Research Center, Siena, Italy) and diluted 1 :2,000 in PBS . Plates were incubated for 3 h at 37°C . After incubation, the wells were washed with 150 ul of 0 .15 M PBS containing 0 .05 % Tween and 0 .02 % sodium azide (PTA), and then 6 ng of PT (affinity purified on a fetuin column as described by Sekura [10] ), in 100 gl of 0 .05 M carbonate buffer (pH 9 .6) was added to each well . Plates were incubated overnight at room temperature in a humidified chamber. The coating buffer was aspirated, and wells were washed with 150 ul of PTA . To minimize nonspecific adsorption of serum proteins to the plastic, wells were coated with 150 wl of a blocking solution consisting of 2 170 BSA in PBS, and then incubated for 2 h at 37°C . Plates were then washed three times in PTA and 100 g1 of fourfold diluted test serum (1 :20-1 :1,280 dilution) and eight twofold serial dilutions of reference serum (1 :20-1 :1,280 dilution) in 0 .15 M PBS containing 0 .1% BSA and 0 .2% sodium azide (PBS-BSA) were added to the wells . The U . S. Reference Pertussis Antiserum (human) containing 200 U/ml of IgG anti-PT was kindly provided by the Center for Drugs and Biologics, Bethesda, MD. After incubation for 1 .5 h at 37'C, plates were washed three times with PTA and 100 g1 of p-nitrophenyl phosphate substrate (Sigma Chemical Co., St . Louis, MO) . 1 mg/ml in 1 M diethanolamine, pH 9 .8, containing 1 MM MgC12, was added to each well . The enzyme-substrate reaction, which developed at room temperature, was stopped after 30 min, and the OD of the samples was measured at 405 nm against a blank (substrate in diethanolamine, pH 9 .8) on a Titertek Multiskan (Flow Laboratories, Inc., McLean, VA) . Controls for each plate included wells with serum samples but no antigen . Each serum sample was tested in duplicate, and absorbance values were averaged . The calculation of the ELISA antibody units in the test samples was determined in relation to the U. S. Reference Pertussis Antiserum (11) .
Antigens . Virulent (phase I) and nonvirulent (phase III) B. pertussis, B. parapertussis, and B. bronchiseptica strains were used together with transposon-induced or deletion B. pertussis mutants lacking one or more virulence-associated antigens (see Table I and Fig . 1 for summary) . Bordetella strains were grown on Bordet-Gengou agar at 35'C for 72 h and Salmonella typhi on LB agar at 37°C overnight . For inactivation, bacteria were harvested from plates, washed in PBS, and resuspended in a 0 .5% formalin solution in PBS and left overnight on a mixer (Coulter Electronics Ltd ., Luton, UK) . After extensive washing, bacteria were resuspended in PBS and stored at 4°C . The OD525 of the suspensions was determined, and the number of cells per milliliter was calculated on previously established standard curves.
Production of hemolysis on BG agar and/or toxic effect on CHO cells (12) were adopted as parameters for the control of phase I Bordetella species .
Soluble PT was purified from B. pertussis phase I culture supernatant as described by Sekura (10), precipitated in ammonium sulfate, and kept at 4°C . Before use, it was resuspended in PBS and heat inactivated (at 100°C for 45 min) .
The 69-kD protein, purified from B. Pertussis outer membrane as previously described (13), was kindly provided by Dr. Novotny (The Wellcome Research Laboratories, Beckenham, UK) .
Mediafor Cell Stimulation and Growth. The culture medium was RPMI 1640 (Gibco Laboratories, Paisley, Scotland) supplemented with L glutamine (2 mM), 1% nonessential amino acids, 1% sodium pyruvate, 50 wg/ml gentamycin, 5 x 10 -5 M 2-ME, and 10% heat-inactivated pooled human AB serum (RPMI-HS) or FCS (RPMI-FCS) . To support the antigenindependent growth of T cell clones, RPMI-HS was supplemented with 50 U/ml human rIL-2 (Hoffman-La Roche, Inc., Nutley, NJ) .
Proliferation Assays. Fycoll-Hypaque (Pharmacia Fine Chemicals AB, Uppsala, Sweden) -separated PBMC were incubated (10 5 cells/well in RPMI-HS) for 6 d with different antigen concentrations in 96-well flat-bottomed Cluster 96 plates (Costar, Cambridge, MA) . When antigen-stimulated T lymphocyte clones were tested, they were incubated at 2 x 10 4 cells/well for 3 d in the presence of 2 x 10 4 mitomycin C-treated EBV transformed autologous B lymphocytes (EBVB cells) and antigens in RPMI-FCS (14 . Cells were then harvested on glass-fiber filters with a cell harvester (Skatron, Lier, Norway), and incorporated radioactivity was determined by liquid scintillation counting.
Cloning ofB. peerttussis-speck TLymphocytes. PBMC isolated from heparinized blood of donor R.R. by Ficoll-Hypaque were cultured in flat-bottomed Cluster 96 plates at the concentration of 105/well in 0.2 ml RPMI-HS in the presence of 106 B, pertussis cells. This antigen concentration was found to induce a strong proliferation response by PBMC from this donor. After 7 d, the activated T cells were expanded in medium supplemented with rIL-2, and after another 7 d, lymphoblasts were cloned by limiting dilution (14) . Cells were seeded at 0.3 per well in Terasaki trays in the presence of 105 allogeneic mitomycin C-treated PBMC, in RPMI-HS containing PHA (1 Itg/ml) and IL-2 . About 50% of the clones obtained proved antigen specific when tested in proliferation assays against B. pertussis. These clones were maintained in culture by periodic restimulation in the presence of allogeneic mitomycin C-treated PBMC, PHA, and rIL-2. T lymphocyte clones were analyzed for cell surface phenotype by direct immunofluorescence on a FRCS (FACStar, Becton Dickinson & Co., Erembodegem, Belgium) . Both phycoerythrin-and fluorescein-conjugated OKT3, OKT4, and OKT8 mAbs (Ortho Diagnostic Systems, Inc., Raritan, NJ) were used.
Immortalization of B Lymphocytes with EBV . PBMC from donor R.R. were transformed with EBV as described (15) . Briefly, 107 PBMC were resuspended in 10 ml RPMI-FCS containing 30% supernatant of the EBV producing marmoset cell line B95.8 and 600 ng/ml cyclosporin A (Sandoz, Basel, Switzerland) and were distributed in a flat-bottomed 96-well plate at 5 x 104/well .
StatisticalAnalysis . The calculation of the ELISA antibody units was based on the parallel line bioassay procedure described by Brownlee (16) using an ELISA unitage calculation program distributed by the Laboratory of Pertussis, Center for Drugs and Biologics, Bethesda, MD. An increase in ELISA units of more than mean negative controls plus 3 SD was arbitrarily considered as a significant level of anti-PT antibodies.
Results of proliferation assays are presented as the mean cpm of triplicate cultures ± SD. Statistical significance was calculated by student's t test.
Results
Identification ofImmune Donors Against B. pertussis. Although no specific serological or cellular tests have been established for the direct measurement of host immunity to pertussis infection, donors with positive and negative anamnesis for whooping cough in childhood were screened for antibody titers against PT by ELISA, and for their proliferative response to B. pertussis . The aim was to identify donors suitable for the generation of T cell clones specific for B. pertussis antigens. As shown in Fig.  2 , all donors with negative anamnesis had very low levels of anti-PT antibodies, when compared with a standard positive reference serum (see reference 11 and Materials and Methods). On the other hand, the levels of anti-PT antibodies in the group with positive anamnesis varied from 0 to 130 U/ml. This clearly indicates that anti-PT antibodies can be found only in a proportion of adults affected by pertussis in childhood (27 .7%), considering as a significant increase in antibody values those higher than the mean of the group with negative anamnesis, plus 3 SD.
Mononuclear cells from peripheral blood of 9 out of 36 positive donors and of 5 out of 16 negative donors were tested for proliferation in response to inactivated whole B. pertussis . As shown in Fig . 3 , a significant proliferation in a dose-dependent fashion was observed in the majority of donors with positive anamnesis; however, some of the negative donors also showed a low, but consistent increase in proliferation in response to B. pertussis antigens. The ELISA units and the maximal proliferation for all the donors tested are reported in Table II , which shows that in -50% of the positive donors, these two parameters correlate, but this is not a general feature. Therefore, these results further confirm the difficulties in identifying immunological tests predictive of the host response against Bordetella infections .
Generation of T Cell Clones Against Whole Inactivated B. pertussis Bacteria. On the basis of these results, a donor with positive anamnesis and high ELISA titers as well as proliferative responses was chosen for the generation ofT cell clones . Thus, PBMC from donor R.R . were stimulated in vitro for 7 d with formalin-killed B. pertussis phase I. The antigen-stimulated cells were then expanded in rIL-2-containing medium and cloned in the presence of PHA and nonautologous feeder cells (14) . Specific clones were identified by means of proliferation in response to killed B. pertussis as shown in Fig . 4 . A total of 12 B. pertussis-specific clones were obtained. Their phenotype was observed to be CD4+8 -, and clones were MHC class 11 restricted, as Antibody levels against PT in serum from normal adults with positive and negative anamnesis for whooping cough during childhood. Shaded area represents mean of negative controls t 3 SD .
demonstrated by inhibition of antigen-induced proliferation by anti-HLA-DR mAbs (data not shown) .
Recognition ofAntigens from Whole Inactivated Bacteria by T Cell Clones. To analyze further the fine specificity of the anti-B. pertussis clones, a panel of Bordetella wildtype strains, as well as mutants, was used as antigen in proliferation tests together with a negative control such as Salmonella typhi (Table I) . A representative experiment with four different T cell clones is shown in Fig. 5 . As expected, the proliferative response ofthe different clones varied according to the panel ofbacterial species used as antigens . A summary of 30 experiments performed is shown in Table III with a tentative prediction of the antigen recognized . On the basis of the reactivity patterns of the clones against Bordetella species and mutants, it can be suggested that clone 6 may recognize FHA. In fact, this clone proliferated in response to phase I Bordetella species, but did not recognize the FHA low producer B. pertussis 353 (7) and the phase III B. bronchiseptica and B. pertussis 347, both totally lacking FHA.
Clones 23 and 32 recognize B. pertussis-specific antigens, since they did not proliferate in response to B. pertussis and B. bronchiseptica . Furthermore, the negative results with phase III B. bronchiseptica and B. pertussis 347 suggest that the antigen(s) recognized is virulence associated . Clones 7, 8, 31 , and 34 recognize virulence-associated Bordetella antigens, since they failed to proliferate in response to phase III B. bronchiseptica and B. pertwsis 347. Finally, clones 9, 17, 26, 28, and 30 recognize nonvirulence- associated Bordetella antigens, since they proliferated in response to all the Bordetella species, regardless of their virulence and antigenic deficiencies . All the clones tested are specific for Bordetella species since they did not recognize inactivated S. typhi.
Since clone 6 was likely to recognize FHA, the analysis of its fine specificity was further extended using two new Bordetella mutants with defined deletions in the structural gene for FHA (see Table I ). As shown in Table IV , clone 6 is capable ofrecognizing B. pertussis FHA 101, but not FHA 102. This would indicate that the determinant recognized by clone 6 is likely to be coded for by the sequence downstream from the second Barn HI site on the FHA structural gene, which represents approximately the COOH-terminal half of the protein. This part is missing in the mutant FHA 102.
Recognition ofSoluble BacterialAntigens by T Cell Clones. The clusters ofclones against B. pertussis-specific antigens (cluster 2) and virulence-associated Bordetella antigens (cluster 3) were then tested against soluble antigens such as PT, which is present only on B. pertussis, and the 69-kD outer membrane protein, which is present on all the three virulent Bordetella species, although with slightly different molecular weights (13) . It was found that clones 23 and 32 from cluster 2 do not proliferate in response to inactivated PT, whereas clones 7, 31, and 34 from cluster 3 were able to recognize the 69-kD protein (Table V) . However, clone 8 from cluster 3 did not proliferate in the presence of the 69-kD protein. Thus, this result would suggest that clone 8 may differ from the other clones of cluster 3 . Its specificity would be directed against an additional virulence-associated, still unknown, Bordetella determinant. T Cell Clones Against PT. Based on the experiments with Bordetella wild species and mutants and on those with soluble bacterial antigens, it can be concluded that none of the T cell clones obtained are against PT. To verify whether this was due to a low frequency or a total lack of such memory T lymphocytes or rather to a deficiency in antigen presentation when whole bacteria were used to stimulate immune PBMC, a new generation of T cell clones from the same R.R . donor was obtained by stimulating his PBMC in vitro with inactivated PT. Table VI shows that, indeed, T cell clones can be obtained against PT. Therefore, a T cell memory exists against PT, but it cannot be evoked by whole bacteria used as antigen.
Discussion
The extraordinary developments in protein chemistry and molecular biology have offered new possibilities in producing safe and effective vaccines . Important results have been obtained regarding methods for development of new vaccines for human and animal diseases, and a recombinant vaccine against hepatitis B is already in use.
Among the priority targets indicated by the World Health Organization to obtain safe and effective vaccines, one of particular interest for both developed and developing countries, is the prevention of pertussis. In fact, this disease had already been efficiently reduced by the cellular vaccine consisting of inactivated B. pertussis bacteria; however, due to its side effects, this vaccine was withdrawn in many countries, resulting in the return of a significant mortality from whooping cough even in highly developed countries (3). Therefore, pertussis represents on the one hand an interesting experimental system, since it is already known that it is possible to actively immunize against the disease and give protection ; furthermore, it is also extremely important to obtain a safe vaccine with high compliance to continue the vaccination campaign . However, the identification of the simplest immunogenic structures capable of conferring a protective immunity is not easy, due to the complexity of the bacterial struc- response such as specific lymphocyte proliferation seems to better correlate with an anamnesis for pertussis and further studies on this aspect are in progress . These preliminary experiments on the characterization ofimmune responses against B. pertussis antigens formed the basis for the identification of an immune donor in order to increase the probability ofobtaining T cell clones against pertussis antigens . Thus, donor R.R. was chosen, and his peripheral blood was used to obtain a first generation of T cell clones directed against Bordetella antigens . To analyze the specificity of these clones, it was decided first to stimulate them with a panel of Bordetella wildtype strains and mutants deficient for some antigens (18) . This approach resulted in clustering the 12 clones obtained in four different groups, which recognized (1) FHA; (2) B. pertussis-specific antigen(s); (3) virulence-associated Bordetella antigen(s) ; and (4) nonvirulence-associated Bordetella antigens . The prediction that cluster 1 recognizes FHA was further confirmed by using two new B. pertussis mutants (D. Relman, unpublished results) that allowed the clone's specificity to be defined for the COOHterminal portion of the FHA protein. Interestingly, the antigen recognized by three clones of cluster 3 was also positively identified as the 69-kD outer membrane protein described by Novotny et al . (13) , while the specificity of the fourth clone seems to be directed to a virulence factor different from the 69-kD protein . In addition, the possibility that cluster 2 recognizes PT, suggested by the experiments with whole inactivated bacteria, was disproved by using soluble PT as antigen. Since cluster
